Introduction: In this study, we aimed to determine the serum, urine, and saliva levels of acyl ghrelin, des-acyl ghrelin, and obestatin in the newly diagnosed idiopathic generalized pediatric epilepsy patients in the pretreatment period and in the third month of valproic acid.
Material And Methods: Thirty pre- and post-treatment cases of patients who were diagnosed with idiopathic generalized epilepsy and 30 control patients were included in this study. Serum, saliva, and urine levels of ghrelin were measured in epileptic group and in the control group in the pretreatment period and in the third month of the treatment.
Results: There were 14 females and 16 males. Mean age was 8.9 ± 2.5 years. Mean body mass index was 17.2 ± 2.3 in the patients and 16.6 ± 2.0 in the control group, whereas it was 16.8 ± 2.1 in the third month of the therapy (P > 0.05). Pretherapy serum, urine, and saliva levels of acyl ghrelin were 36.45 ± 9.93, 31.78 ± 12.87, and 34.23 ± 11.49 pg/mL, respectively in the patient group. Post-treatment serum, urine, and saliva levels of acyl ghrelin were 51.34 ± 12.01, 48.24 ± 16.76, and 44.90 ± 14.99 pg/mL in the patient group. Pretherapy serum, urine, and saliva levels of des-acyl ghrelin were 419.62 ± 75.63, 370.59 ± 60.11, and 396.28 ± 60.76 pg/mL, respectively in the patient group. Post-therapy serum, urine, and saliva levels of des-acyl ghrelin were 458.61 ± 87.10, 429.92 ± 55.81, and 449.48 ± 74.32 pg/mL, respectively in the patient group. Pretherapy serum, urine, and saliva levels of obestatin were 23.02 ± 3.15, 14.27 ± 4.22, and 29.52 ± 5.39 ng/mL, respectively. Post-therapy serum, urine, and saliva levels of obestatin were 24.30 ± 4.18, 15.27 ± 6.43, and 30.94 ± 7.42 ng/mL, respectively.
Conclusion: There was a significant increase in the serum, urine, and saliva levels of acyl ghrelin and des-acyl ghrelin without an increase in post-therapy body mass index in idiopathic generalized epilepsy patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pediatrneurol.2014.05.014 | DOI Listing |
J Vet Intern Med
January 2025
Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Background: The pathophysiology of polyuria and polydipsia secondary to exogenous glucocorticoid excess is incompletely understood.
Objective: Investigate plasma AVP (pAVP) and serum CoP (sCoP) concentrations in healthy dogs before, during, and after abrupt discontinuation of a long-term course of orally administered prednisolone.
Animals: Eight healthy neutered young adult research Beagles.
J Vet Emerg Crit Care (San Antonio)
January 2025
Department of Veterinary Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, Davis, California, USA.
Objective: To describe the acid-base balance of diabetic animals with ketosis and to identify underlying mechanisms of acid-base changes using semiquantitative analysis.
Design: Retrospective study.
Setting: University teaching hospital.
Urol Case Rep
January 2025
Department of Urology, the Affiliated Hospital of Qingdao University, Qingdao, 266550, China.
This case highlights the effective use of retroperitoneal laparoscopic partial nephrectomy (RLPN) in a 73-year-old female with two large renal carcinomas in her solitary kidney, including a 7 cm deeply infiltrating mass. The RLPN procedure successfully resected both tumors with a thermal ischemia time of 28 minutes, 110 minutes of surgery, and only 30 mL of blood loss. The patient's postoperative recovery was excellent, with no hemorrhage or urine leakage and only a mild increase in serum creatinine levels.
View Article and Find Full Text PDFJ Res Pharm Pract
December 2024
Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran.
Objective: This study investigates the impact of omeprazole on urinary magnesium (Mg) excretion in children undergoing treatment for peptic disease. Specifically, it examines how omeprazole influences the fractional excretion of Mg.
Methods: This single-arm clinical trial was conducted from 2020 to 2021.
Cureus
December 2024
Business Development Hospitals, Wockhardt Hospitals Ltd., Mumbai, IND.
Background and objectives The persistent nature of diabetic foot ulcers (DFUs) is mainly attributable to compromised wound healing mechanisms, which are aggravated due to poor blood flow, neuropathy, and infection. Growth factors have become essential agents in the treatment of DFUs, serving as primary mediators that enhance wound healing through the stimulation of cell proliferation, migration, and angiogenesis. This prospective open-label, randomised, comparative, multi-centre, investigator-initiated study compared the safety and effectiveness of adjuvant therapy with topical application of autologous growth factor concentrate (AGFC) using the Healrex therapy kit (Wockhardt, India) versus standard of care (SoC) in DFUs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!